Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [524]
News [1468]
Articles [68]
Editorials [2]
Conferences [72]
elearning [5]
History of epidermal stem cell use in the clinical setting
Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy
History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )
14 Dec 2012
Analysing the efficacy of treatment through Response Evaluation Criteria in...
Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012
Phase III MISSION trial: Sorafenib does not extend overall survival as third or...
Dr Tony Mok – The Chinese University of Hong Kong
Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer ( Dr Tony Mok – The Chinese University of Hong Kong )
8 Oct 2012
Trametinib and dabrafenib combination therapy against metastatic melanoma
Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia
Trametinib and dabrafenib combination therapy against metastatic melanoma ( Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia )
8 Oct 2012
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib...
Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma ( Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia )
29 Sep 2012
Phase I and II trials focus on drug combination slowing development of...
Prof Yossef Yarden - Weizmann Institute of Science, Israel.
Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF ( Prof Yossef Yarden - Weizmann Institute of Science, Israel. )
29 Sep 2012
The immuno side of melanoma
Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
The immuno side of melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
16 Jul 2012
MEK inhibitor, trametinib, improves progression free survival in melanoma
Dr Caroline Robert – Institute Gustave Roussy, Paris, France
MEK inhibitor, trametinib, improves progression free survival in melanoma ( Dr Caroline Robert – Institute Gustave Roussy, Paris, France )
18 Jun 2012
Treating metastatic melanoma with vemurafenib
Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA
Treating metastatic melanoma with vemurafenib ( Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA )
15 Jun 2012
New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma
Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany
New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma ( Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany )
4 Jun 2012
New MEK inhibitor, trametinib, improves survival in advanced melanoma
Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France
New MEK inhibitor, trametinib, improves survival in advanced melanoma ( Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France )
4 Jun 2012
Early results from new PD-1 targeted immune therapy
Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore...
Early results from new PD-1 targeted immune therapy ( Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA )
2 Jun 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation